Irish biotech col­lects $75M in Se­ries B to start Phase 3 rare joint tu­mor tri­al

Syn­Ox Ther­a­peu­tics has com­plet­ed a $75 mil­lion Se­ries B raise to ad­vance its mon­o­clon­al an­ti­body drug through a reg­is­tra­tional tri­al for a type of non-can­cer­ous growth.

The fundraise – co-led by For­bion and Health­Cap with new in­vestor Bio­qube Ven­tures – will sup­port the de­vel­op­ment of emac­tuzum­ab in tenosyn­ovial gi­ant cell tu­mor (TGCT).

TGCT is caused by chro­mo­so­mal ab­nor­mal­i­ties that trig­ger over­pro­duc­tion of CSF-1 pro­tein, which sup­press­es the body’s T cell-me­di­at­ed im­mune re­sponse against tu­mors. “Pa­tients have these large, in­va­sive tu­mors that dis­rupt all as­pects of their lives,” from re­strict­ed mo­bil­i­ty to con­sid­er­able pain, Syn­Ox CEO Ray Bar­low told End­points News in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER